2022 World Conference on Lung Cancer (ePosters)-EP08.01-108. Real-Life Costs and Benefit of First-Line Pembrolizumab for Advanced NSCLC - A Propensity-Score Matched Case-Control Study

EP08.01-108. Real-Life Costs and Benefit of First-Line Pembrolizumab for Advanced NSCLC - A Propensity-Score Matched Case-Control Study

Back to course

Pdf Summary

A recent study conducted at Kepler University Hospital in Austria compared the real-life costs and benefits of first-line pembrolizumab immunotherapy to chemotherapy for advanced non-small cell lung cancer (NSCLC). Pembrolizumab is a monoclonal antibody that targets a receptor involved in immune regulation. The study aimed to evaluate the effectiveness and costs of pembrolizumab treatment by comparing a cohort of patients who received pembrolizumab to a matched historical cohort who received chemotherapy.<br /><br />The study retrospectively analyzed 93 patients who received pembrolizumab as either monotherapy or in combination with chemotherapy between 2017 and 2019. These patients were compared to a group of patients from the institutional lung cancer registry who received chemotherapy between 2011 and 2016. Patients who received pembrolizumab in later therapy lines were excluded from the analysis.<br /><br />The results showed that patients treated with pembrolizumab had significantly longer progression-free and overall survival compared to those treated with chemotherapy alone. However, the pembrolizumab treatment was associated with considerably higher costs. The average therapy costs per patient were over four times higher in the pembrolizumab group compared to the chemotherapy group.<br /><br />The study also analyzed the costs of extending progression-free survival (PFS) and overall survival (OS) with pembrolizumab therapy compared to chemotherapy. The costs for one additional month of PFS and OS with pembrolizumab were calculated to be significantly higher compared to chemotherapy.<br /><br />This study highlights the benefits of pembrolizumab immunotherapy as a first-line treatment for advanced NSCLC, showing improved survival outcomes compared to chemotherapy. However, these benefits come with higher treatment costs. The findings provide valuable real-world evidence to inform treatment decisions and cost considerations in the management of advanced NSCLC.

Asset Subtitle

Vanessa Rambousek

Meta Tag

Speaker Vanessa Rambousek

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Kepler University Hospital

Austria

pembrolizumab immunotherapy

chemotherapy

advanced non-small cell lung cancer

NSCLC

monoclonal antibody

immune regulation

progression-free survival

overall survival